Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones

Janney Montgomery Scott Upgrades Agios Pharma (AGIO) to Buy

February 16, 2017 1:39 PM EST

Janney Montgomery Scott earlier upgraded Agios Pharma (NASDAQ: AGIO) from Neutral to Buy with a price target of $57.00.

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $46.12 yesterday.

... More

Agios Pharma (AGIO) Tops Q4 EPS by 17c

February 16, 2017 7:04 AM EST

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.34), $0.17 better than the analyst estimate of ($1.51). Revenue for the quarter came in at $22.65 million versus the consensus estimate of $10.89 million.

"Our 2016 accomplishments, including the enasidenib NDA submission with our collaboration partner Celgene and clear proof-of-concept... More